JP2020535791A - 健常および病変心筋細胞の成熟状態を増強するための組成物および方法 - Google Patents

健常および病変心筋細胞の成熟状態を増強するための組成物および方法 Download PDF

Info

Publication number
JP2020535791A
JP2020535791A JP2020509099A JP2020509099A JP2020535791A JP 2020535791 A JP2020535791 A JP 2020535791A JP 2020509099 A JP2020509099 A JP 2020509099A JP 2020509099 A JP2020509099 A JP 2020509099A JP 2020535791 A JP2020535791 A JP 2020535791A
Authority
JP
Japan
Prior art keywords
cardiomyocytes
stem cell
derived
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020509099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535791A5 (enExample
Inventor
トク−ホ キム
トク−ホ キム
ジェシー マカダングダン
ジェシー マカダングダン
アレック エス．ティー． スミス
アレック エス．ティー． スミス
ハンネレ ルオホラ−ベイカー
ハンネレ ルオホラ−ベイカー
ジェイソン ウェイン ミクラス
ジェイソン ウェイン ミクラス
Original Assignee
ユニヴァーシティ オブ ワシントン
ユニヴァーシティ オブ ワシントン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ ワシントン, ユニヴァーシティ オブ ワシントン filed Critical ユニヴァーシティ オブ ワシントン
Publication of JP2020535791A publication Critical patent/JP2020535791A/ja
Publication of JP2020535791A5 publication Critical patent/JP2020535791A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/375—Thyroid stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2535/00—Supports or coatings for cell culture characterised by topography
    • C12N2535/10—Patterned coating
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
JP2020509099A 2017-08-16 2018-08-16 健常および病変心筋細胞の成熟状態を増強するための組成物および方法 Pending JP2020535791A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762546438P 2017-08-16 2017-08-16
US62/546,438 2017-08-16
PCT/IB2018/056169 WO2019035032A2 (en) 2017-08-16 2018-08-16 COMPOSITIONS AND METHODS FOR ENHANCING THE MATURATION OF HEALTHY AND ILL HEART CARDIOMYCYTES

Publications (2)

Publication Number Publication Date
JP2020535791A true JP2020535791A (ja) 2020-12-10
JP2020535791A5 JP2020535791A5 (enExample) 2021-09-30

Family

ID=65362375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020509099A Pending JP2020535791A (ja) 2017-08-16 2018-08-16 健常および病変心筋細胞の成熟状態を増強するための組成物および方法

Country Status (6)

Country Link
US (1) US20200224168A1 (enExample)
EP (1) EP3664821A4 (enExample)
JP (1) JP2020535791A (enExample)
KR (1) KR20200039707A (enExample)
CN (1) CN111246863A (enExample)
WO (1) WO2019035032A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019113432A1 (en) * 2017-12-08 2019-06-13 University Of Washington Methods and compositions for detecting and promoting cardiolipin remodeling and cardiomyocyte maturation and related methods of treating mitochondrial dysfunction
EP3941496A4 (en) * 2019-03-18 2022-11-23 University of Washington METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS
WO2022010049A1 (ko) * 2020-07-09 2022-01-13 주식회사 티앤알바이오팹 인간 전분화능줄기세포 유래 심근세포를 이용한 SARS-CoV-2 바이러스 대상 후보 약물의 심근세포 독성 평가용 조성물 및 이를 이용한 심근세포 독성 평가 방법
US12173322B2 (en) 2020-12-09 2024-12-24 The University Of Queensland Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof
WO2023183371A2 (en) * 2022-03-22 2023-09-28 The Trustees Of Columbia University In The City Of New York Engineered heart tissue model of restrictive cardiomyopathy for drug discovery

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
JP2016518117A (ja) * 2013-03-15 2016-06-23 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 導電性細胞のためのマイクロ電極アレイを含むデバイスおよび方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844354B2 (en) * 2014-06-06 2020-11-24 Ncardia B.V. Cardiomyocyte maturation
CN106148284A (zh) * 2015-03-23 2016-11-23 苏州博瑞斯坦生物医药有限公司 小分子定向组织和器官再生的多能人类干细胞技术、方法和产品

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518117A (ja) * 2013-03-15 2016-06-23 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 導電性細胞のためのマイクロ電極アレイを含むデバイスおよび方法
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. MOL. CELL CARDIOL., vol. 72, JPN6022032343, 2014, pages 296 - 304, ISSN: 0005051929 *
PROC. NATL. ACAD. USA, vol. 112, JPN6022032344, 2015, pages 2785 - 2794, ISSN: 0005051928 *

Also Published As

Publication number Publication date
CN111246863A (zh) 2020-06-05
EP3664821A4 (en) 2021-06-09
WO2019035032A3 (en) 2019-04-25
US20200224168A1 (en) 2020-07-16
EP3664821A2 (en) 2020-06-17
KR20200039707A (ko) 2020-04-16
WO2019035032A2 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
Xie et al. Transient HIF2A inhibition promotes satellite cell proliferation and muscle regeneration
Kita-Matsuo et al. Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes
JP2020535791A (ja) 健常および病変心筋細胞の成熟状態を増強するための組成物および方法
Chen et al. Modulation of mGluR-dependent MAP1B translation and AMPA receptor endocytosis by microRNA miR-146a-5p
CN111500665A (zh) 来自患者的诱导性多能干细胞的心肌细胞及其使用方法
BR112020010079A2 (pt) composições celulares e métodos de tratamento i
WO2014201254A1 (en) Methods for maturing cardiomyocytes and uses thereof
Dark et al. Generation of left ventricle-like cardiomyocytes with improved structural, functional, and metabolic maturity from human pluripotent stem cells
US20120213751A1 (en) Novel stem cells, nucleotide sequences and proteins therefrom
US20220152278A1 (en) Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown
US20230392124A1 (en) Methods and compositions for improving sc-beta cells or enhancing their utility
Macadangdang et al. Engineered developmental niche enables predictive phenotypic screening in human dystrophic cardiomyopathy
WO2017177050A1 (en) Direct reprogramming of somatic cells into myogenic cells
Riuzzi et al. S100B protein in skeletal muscle regeneration: regulation of myoblast and macrophage functions.
JP2024525542A (ja) 横紋筋細胞の弛緩を改善するための方法
WO2020190939A1 (en) Methods of promoting cellular maturation with ampk activators
US11821003B2 (en) Cardiogenic mesoderm formation regulators
KR102012943B1 (ko) 마이크로rna의 비정규 표적을 억제하는 rna 간섭 유도 핵산 및 그 용도
US11672830B2 (en) MicroRNA-294 and Lin28A as a driver of cardiac tissue proliferation in response to pathological injury
US12173322B2 (en) Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof
Lopez Investigating the Molecular Mechanisms Involved in the Mechanosensation of Neural Stem Cell Differentiation
Limpitikul et al. Influence of electromechanical activity on cardiac differentiation of mouse embryonic stem cells
Balakrishnan et al. SMPD3-mediated extracellular vesicle biogenesis inhibits oligodendroglioma growth
Hoh Research into the physiology of myosins-a personal odyssey
Huntington Development of RNA therapeutics for cardiac regeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200720

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509